ACEI/ARB+ finerenone

ApprovedSmall molecule

FFirst Affiliated Hospital, Sun Yat-Sen University

ACEI/ARB+ finerenone is one of 36 small molecule programs targeting Membranous Nephropathy. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Membranous NephropathyActive, not recruiting

Membranous NephropathyApproved

Active, not recruiting

Competition

Competitive Landscape

75 competitors in Membranous Nephropathy

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

16 2

Neoral

Novartis

Phase 3

4 3

Gazyva

Roche

Phase 3

3 4

Medrol

Pfizer

Phase 3

2 5

Prograf

VVeloxis Pharmaceuticals

Phase 3

6 6

Brukinsa

BBeOne Medicines

Phase 3

1 7

Benadryl

Felzartamab

1 9

Tylenol

KKenvue Brands

Phase 3

—10

Povetacicept

Vertex Pharmaceuticals

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Membranous Nephropathy1 trial

Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy

Not yet recruiting·FFirst Affiliated Hospital, Sun Yat-Sen University·Phase 4·NCT06573411·88 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ACEI/ARB+ finerenone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ACEI/ARB+ finerenone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ACEI/ARB+ finerenone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — First Affiliated Hospital, Sun Yat-Sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: FFirst Affiliated Hospital, Sun Yat-Sen University

ACEI/ARB+ finerenone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Membranous Nephropathy1 trial

References

Drug Info

Quick Facts

Related News